Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up

Ann Oncol. 1995 Jan;6(1):90-1. doi: 10.1093/oxfordjournals.annonc.a059059.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Fluorouracil / administration & dosage
  • Follow-Up Studies
  • Humans
  • Medroxyprogesterone Acetate / administration & dosage
  • Middle Aged
  • Prospective Studies
  • Survival Rate

Substances

  • Doxorubicin
  • Cyclophosphamide
  • Medroxyprogesterone Acetate
  • Fluorouracil